Glenmark Pharmaceutical launches Tiogiva in UK for COPD treatment
Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive pulmonary disease (COPD). Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler. As per data from IQVIA, Tiotropium DPI’s market size was $450 million in the European […]